Immunocore Holdings Plc · NASDAQ:IMCR
Immunocore — Q2 2023 Earnings Presentation
26 slides from Immunocore's earnings presentation, Aug 10, 2023
Slide 1: 2Q 2023 Financial Results & Business Update
2Q 2023 Financial Results & Business Update Thursday, August 10, 2023
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate” and similar expressions (as well as ot
Slide 3: Agenda
Agenda 3 Overview & 2Q Highlights Bahija Jallal, PhD – Chief Executive Officer 2Q Financial Results KIMMTRAK® Commercial Execution Pipeline & PRISM Phase 3 Trial Design Looking Ahead Brian Di Donato – Chief Financial Officer & Head of Strategy Ralph Torbay – Head of Commercial David Berman, MD, PhD
Slide 4: Our mission
4 Our mission To radically improve outcomes for patients with cancer, infectious diseases, and autoimmune conditions by pioneering and delivering transformative medicines
Slide 5: 1H 2023 Highlights
1. Projection based on the current business plan, includes projected KIMMTRAK net revenues. Immunocore may have based this estimate on assumptions that are incorrect and may end up using its resources sooner than anticipated, including as a result of increased costs or milestone payments that may be
Slide 6: 2Q 2023 Financials
2Q 2023 Financials BRIAN DI DONATO CFO & Head of Strategy 6
Slide 7: 2Q 2023 Financials Key Figures
1. Projection based on the current business plan, includes projected KIMMTRAK/tebentafusp net revenues. Immunocore may have based this estimate on assumptions that are incorrect and may end up using its resources sooner than anticipated, including as a result of increased costs or milestone payments
Slide 8: KIMMTRAK Execution
KIMMTRAK ® Execution RALPH TORBAY Head of Commercial 8
Slide 9: KIMMTRAK continues to grow in key markets
KIMMTRAK® continues to grow in key markets 1. ROW (International) denotes countries where Immunocore is commercializing through a partner; 2. In millions. $ figures are based on "convenience" rates of 1.3152 for Q1 2022, 1.2162 for Q2 2022, 1.1134 for Q3 2022, 1.2077 for Q4 2022,1.2369 for Q1 2023,
Slide 10: Most prescribed HLA-A02 mUM medicine in all launch countries
Most prescribed HLA-A02 mUM* medicine in all 7 launch countries 1. ROW (International) denotes countries where Immunocore is commercializing through a partner; 2. In millions. $ figures are based on "convenience" rates of 1.2709 for Q2 2023 applied to £ figures reported. *Commercial launches ongoing
Slide 11: KIMMTRAK: Looking ahead
KIMMTRAK: Looking ahead * Subject to reimbursement discussions 1. Recovering Excessive Funds for Unused and Needless Drugs Act of 2021 or the REFUND Act 11 Growth US community expansion 1L KIMMTRAK 3-yrs OS data expected 4Q Expansion in Italy Several additional launches expected in Europe* Reimburse
Slide 12: Pipeline & PRISM-MEL301 Trial
Pipeline & PRISM-MEL301 Trial DAVID BERMAN Head of Research and Development 12
Slide 13: Multiple candidates in oncology and infectious diseases
1. Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world. * Platinum refractory or resistant serous ovarian carcinoma 13 Multiple candidates in oncology and infec
Slide 14: ctDNA reduction in 1st line and 2nd+ line mUM
Carvajal, R.D., et. al. Nat Med 28, 2364–2373 (2022) Sullivan R, et. Al. Cancer Res (2023) 83 (7_Supplement): 1035. 14 ctDNA reduction in 1st line (Ph 3) and 2nd+ line (Ph 2) mUM KIMMTRAK clinical activity highest in early stage disease 1st line (N=123) 2nd + line (N=94) Where possible, study in ear
Slide 15: Longest OS follow-up for any bispecific TCR therapy
Sacco J, et al. Cancer Res (2023) 83 (8_Supplement): CT223. 15 Longest OS follow-up for any bispecific TCR therapy 3-yr OS in previously-treated (Ph 2) mUM remains higher than historical Long term OS benefit emerging – consistent with other IO therapies Platform insight KIMMTRAK® (tebentafusp) (N=12
Slide 16: In cutaneous melanoma, tebentafusp active with checkpoints
Hamid O, et al. JITC (2023) * Patients who received prior anti-PD(L)1 therapy and then received tebentafusp+ durvalumab +/- tremelimumab on Study IMCgp100-201. Included patients relapsed from or refractory to prior anti-PD(L)1 16 AE incidence/severity consistent with that of each therapy alone (IMCg
Slide 17: IMC-F106C (PRAME) clinical program progress
Endometrial Monotherapy expansion NSCLC Monotherapy expansion Ovarian Monotherapy expansion Cutaneous melanoma Monotherapy expansion IMC-F106C (PRAME) clinical program progress 17 Monotherapy Standards-of-care combinations Checkpoint inhibitor combinations ImmTAC combination Chemotherapy combination
Slide 18: IMC-F106C monotherapy melanoma activity
18 Melanoma patients as presented at ESMO 2022 (n=18) IMC-F106C monotherapy melanoma activity Durable response Durable disease control Melanoma type PRAME status Prior therapy Cutaneous (n=7) 5+, 1 unknown; 1 negative All prior anti-PD1 & ipilimumab Uveal (n=5) All + Prior tebentafusp Uveal (n=6) Al
Slide 19: IMC-F106C monotherapy melanoma activity shows durability
Data cut-off May 2023 from live data base DoR= duration of response ^ Patient had disease progression after Month 12 19 Update to original ESMO melanoma patients (n=18) IMC-F106C monotherapy melanoma activity shows durability Durable response Radiation to index lesion after this date DoR = 10 mo^ Do
Slide 20: Reasons to initiate IMC-F106C + anti-PD1 Ph3 trial in 1L melanoma
Reasons to initiate IMC-F106C + anti-PD1 Ph3 trial in 1L melanoma 20 Successful Type B FDA meeting – Agreement to Ph3 trial & dose optimization (Project Optimus) Monotherapy durable responses and disease control in heavily pre-treated melanoma, supportive of PFS (supported by emerging data in new pa
Slide 21: PRISM-MEL301: First line advanced cutaneous melanoma Phase 3
a. Use of nivolumab or nivolumab+relatlimab as control will be country specific b. Represents target dose after intra-patient dose escalation c. ITT: intent to treat 21 Design based on Type B FDA meeting PRISM-MEL301: First line advanced, cutaneous melanoma Phase 3 Previously untreated, advanced mel
Slide 22: Executing across core areas for PRAME program
Executing across core areas for PRAME program 22 Endometrial Monotherapy expansion NSCLC Monotherapy expansion Ovarian Monotherapy expansion Cutaneous melanoma Monotherapy expansion Monotherapy Standard-of-care combinations Checkpoint inhibitor combinations Chemotherapy combinations 40 mcg dose opti
Slide 23: Looking Ahead
Looking Ahead Bahija Jallal Chief Executive Officer 23
Slide 24: Planned Commercial and Clinical Milestones
Commercial Milestones Planned Commercial Milestones KIMMTRAK® Commercial launch in Italy, Austria, Finland, and Israel Launches in several additional European countries Pricing reimbursement agreement in Germany Pricing reimbursement agreement in France CLINICAL Milestones Planned Commercial Milesto
Slide 25: Q&A Session
BAHIJA JALLAL PhD Chief Executive Officer Q&A Session BRIAN DI DONATO Chief Financial Officer and Head of Strategy DAVID BERMAN MD, PhD Head of Research and Development RALPH TORBAY Head of Commercial 25 MOHAMMED DAR MD SVP, Clinical Development and Chief Medical Officer
Slide 26: — O > < = — -7 _
— O > < = — -7 _